HRP20161351T1 - Derivati spirotienopiranopiperidina kao antagonisti receptora orl-1, namijenjeni upotrebi u liječenju ovisnosti o i zloupotrebi alkohola - Google Patents
Derivati spirotienopiranopiperidina kao antagonisti receptora orl-1, namijenjeni upotrebi u liječenju ovisnosti o i zloupotrebi alkohola Download PDFInfo
- Publication number
- HRP20161351T1 HRP20161351T1 HRP20161351TT HRP20161351T HRP20161351T1 HR P20161351 T1 HRP20161351 T1 HR P20161351T1 HR P20161351T T HRP20161351T T HR P20161351TT HR P20161351 T HRP20161351 T HR P20161351T HR P20161351 T1 HRP20161351 T1 HR P20161351T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- compound
- ylmethyl
- fluorine
- hydrogen
- Prior art date
Links
- 208000007848 Alcoholism Diseases 0.000 title claims 7
- 208000025746 alcohol use disease Diseases 0.000 title claims 4
- 206010001584 alcohol abuse Diseases 0.000 title claims 2
- 201000007930 alcohol dependence Diseases 0.000 title claims 2
- 108010020615 nociceptin receptor Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- -1 cyano, cyanomethyl Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- NKQHBJNRBKHUQR-UHFFFAOYSA-N [2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]pyridin-3-yl]methanol Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=NC=CC=C1CO NKQHBJNRBKHUQR-UHFFFAOYSA-N 0.000 claims 2
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 claims 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims 1
- QTOTZWFQCWGMHS-UHFFFAOYSA-N 2-chloro-1'-[[1-(2,6-difluorophenyl)-3-methylpyrazol-4-yl]methyl]-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1F QTOTZWFQCWGMHS-UHFFFAOYSA-N 0.000 claims 1
- AOVBNGOCCRPLFB-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[1-(3-fluoropyridin-2-yl)-3-methylpyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=NC=CC=C1F AOVBNGOCCRPLFB-UHFFFAOYSA-N 0.000 claims 1
- TVSCFMXJYNZEER-UHFFFAOYSA-N 7-methoxy-11a-methyl-1,9b,10,11-tetrahydronaphtho[1,2-g]indole Chemical compound C1CC2(C)CC=NC2=C2C=CC3=CC(OC)=CC=C3C21 TVSCFMXJYNZEER-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004859 cyclopropyloxymethyl group Chemical group C1(CC1)OC* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Claims (8)
1. Spoj formule:
[image]
,
ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja upotrebe alkohola;
te što
A je
[image]
ili
[image]
;
R1 je fluor ili klor;
svaki od R2a i R2b je vodik ili fluor;
R3 je vodik, metil, hidroksimetil ili (C1-C3) alkoksimetil;
R4 se bira iz skupine koju čine fluor, klor, cijano, cijanometil, (C1-C3) alkil, ciklopropil, hidroksimetil, metoksi, ciklopropilmetoksi, aminokarbonilmetoksi, (C1-C3) alkoksimetil, ciklopropiloksimetil, ciklopropilmetoksimetil, 1-hidroksi-1-metiletil, aminokarboniloksimetil, metilaminokarboniloksimetil, dimetilaminokarboniloksimetil, aminokarbonil, aminokarbonilmetil, -CH2-NR5R6, hidroksiimin, metoksiimin, morfolin-4-il, morfolin-4-ilmetil, Ar1, -CH2Ar1, tetrahidrofuran-2-il, 3-oksomorfolin-4-ilmetil, 2-oksopirolidin-1-ilmetil i 2-oksopiperidin-1-ilmetil;
R4′ se bira iz skupine koju čine fluor, klor, cijano, cijanometil, (C1-C3) alkil, ciklopropil, hidroksimetil, metoksi, metoksimetil, aminokarboniloksimetil, metilaminokarboniloksimetil, dimetilaminokarboniloksimetil, metilkarbonil, aminokarbonil, metilaminokarbonil, dimetilaminokarbonil, -NR5′R6, -CH2-NR5′R6, morfolin-4-il, morfolin-4-ilmetil, Ar2, -CH2Ar2, 3,3-difluorazetidin-1-ilmetil, pirolidin-1-ilmetil, 1-aminociklopropil, 1-metilaminociklopropil i 1-dimetilaminociklopropil;
R5 je vodik, C1-C3 alkil, cijanometil, -C(O)CH3 ili aminokarbonilmetil;
R5′ je vodik, C1-C4 alkil, ciklopropil, hidroksietil, metoksietil, -C(O)CH3 ili -C(O)O(C1-C3) alkil;
R6 je vodik ili metil;
R7 je vodik, fluor, klor, metil, hidroksimetil ili metoksi;
Ar1 je ostatak kojeg se bira iz skupine koju čine imidazol-1-il, imidazol-2-il, 2-metilimidazol-1-il, pirazol-1-il, 1,2,3-triazol-1-il; 1,2,3-triazol-2-il; 1,2,4-triazol-1-il, isoksazol-3-il, oksazol-5-il i 3-metil-1,2,4-oksadiazol-5-il; i
Ar2 je ostatak kojeg se bira iz skupine koju čine imidazol-1-il, imidazol-2-il, 2-metilimidazol-1-il, 1-metilimidazol-2-il i 1,2,4-triazol-3-il.
2. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je svaki od R2a i R2b fluor.
3. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što je R1 klor, a R3 je metil ili hidroksimetil.
4. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što je R3 metil.
5. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je spoj
[2-[4-[(2-klor-4,4-difluorspiro[5H-tieno[2,3-c]piran-7,4′-piperidin]-1′-il)metil]-3-metilpirazol-1-il]-3-piridil]metanol,
2-klor-4,4-difluor-1′-[[1-(3-fluor-2-piridil)-3-metilpirazol-4-il]metil]spiro[5H-tieno[2,3-c]piran-7,4′-piperidin], ili
2-klor-1′-[[1-(2,6-difluorfenil)-3-metilpirazol-4-il]metil]-4,4-difluorspiro[5H-tieno[2,3-c]piran-7,4′-piperidin],
ili njihove farmaceutski prihvatljive soli.
6. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je spoj [2-[4-[(2-klor-4,4-difluorspiro[5H-tieno[2,3-c]piran-7,4′-piperidin]-1′-il)metil]-3-metilpirazol-1-il]-3-piridil]metanol, ili njegova farmaceutski prihvatljiva sol.
7. Spoj, ili sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je poremećaj upotrebe alkohola ovisnost o alkoholu.
8. Spoj, ili sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je poremećaj upotrebe alkohola zloupotreba alkohola.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161567242P | 2011-12-06 | 2011-12-06 | |
PCT/US2012/066918 WO2013085781A1 (en) | 2011-12-06 | 2012-11-29 | Spirothienopyran- piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse |
EP12795315.6A EP2787995B1 (en) | 2011-12-06 | 2012-11-29 | Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161351T1 true HRP20161351T1 (hr) | 2016-12-02 |
Family
ID=47279166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161351TT HRP20161351T1 (hr) | 2011-12-06 | 2016-10-17 | Derivati spirotienopiranopiperidina kao antagonisti receptora orl-1, namijenjeni upotrebi u liječenju ovisnosti o i zloupotrebi alkohola |
Country Status (28)
Country | Link |
---|---|
US (1) | US9371335B2 (hr) |
EP (1) | EP2787995B1 (hr) |
JP (1) | JP6002778B2 (hr) |
KR (1) | KR101638265B1 (hr) |
CN (1) | CN103987387B (hr) |
AP (1) | AP3880A (hr) |
AU (1) | AU2012348140B2 (hr) |
BR (1) | BR112014012849A2 (hr) |
CA (1) | CA2853500C (hr) |
DK (1) | DK2787995T3 (hr) |
EA (1) | EA022874B1 (hr) |
ES (1) | ES2600911T3 (hr) |
HK (1) | HK1196943A1 (hr) |
HR (1) | HRP20161351T1 (hr) |
HU (1) | HUE029439T2 (hr) |
IL (1) | IL232654A (hr) |
LT (1) | LT2787995T (hr) |
MX (1) | MX352997B (hr) |
MY (1) | MY172809A (hr) |
PL (1) | PL2787995T3 (hr) |
PT (1) | PT2787995T (hr) |
RS (1) | RS55182B1 (hr) |
SG (1) | SG11201402745UA (hr) |
SI (1) | SI2787995T1 (hr) |
TW (1) | TWI582096B (hr) |
UA (1) | UA113859C2 (hr) |
WO (1) | WO2013085781A1 (hr) |
ZA (1) | ZA201403927B (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR105821A1 (es) * | 2015-09-09 | 2017-11-15 | Lilly Co Eli | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T |
DK3589637T3 (da) * | 2017-03-02 | 2021-06-14 | Lilly Co Eli | Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T |
PL3589638T3 (pl) | 2017-03-02 | 2021-09-27 | Eli Lilly And Company | Związki użyteczne do hamowania ror-gamma-t |
CN109400618B (zh) * | 2018-11-09 | 2021-08-10 | 中国药科大学 | 一种色满衍生物及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5140032A (en) * | 1990-10-01 | 1992-08-18 | Radecki Thomas E | Drug therapy for alcohol abusers |
EP1873150A1 (en) * | 2006-06-30 | 2008-01-02 | Nikem Research S.R.L. | Fluorinated indoleamides useful as ligands of the ORL-1 receptor |
EP2089030B1 (en) * | 2006-10-16 | 2011-09-14 | Mitsubishi Tanabe Pharma Corporation | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
CA2781041C (en) * | 2009-11-16 | 2015-01-06 | Eli Lilly And Company | Spiropiperidine compounds as orl-1 receptor antagonists |
UA107943C2 (en) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Compounds of spiropiperidines as antagonists of the orl-1 receptors |
-
2012
- 2012-11-20 TW TW101143326A patent/TWI582096B/zh not_active IP Right Cessation
- 2012-11-29 PL PL12795315T patent/PL2787995T3/pl unknown
- 2012-11-29 EA EA201490938A patent/EA022874B1/ru not_active IP Right Cessation
- 2012-11-29 LT LTEP12795315.6T patent/LT2787995T/lt unknown
- 2012-11-29 DK DK12795315.6T patent/DK2787995T3/en active
- 2012-11-29 KR KR1020147014889A patent/KR101638265B1/ko active IP Right Grant
- 2012-11-29 ES ES12795315.6T patent/ES2600911T3/es active Active
- 2012-11-29 SI SI201230690A patent/SI2787995T1/sl unknown
- 2012-11-29 RS RS20160772A patent/RS55182B1/sr unknown
- 2012-11-29 BR BR112014012849A patent/BR112014012849A2/pt not_active IP Right Cessation
- 2012-11-29 CA CA2853500A patent/CA2853500C/en not_active Expired - Fee Related
- 2012-11-29 MY MYPI2014701471A patent/MY172809A/en unknown
- 2012-11-29 UA UAA201405536A patent/UA113859C2/uk unknown
- 2012-11-29 EP EP12795315.6A patent/EP2787995B1/en active Active
- 2012-11-29 PT PT127953156T patent/PT2787995T/pt unknown
- 2012-11-29 WO PCT/US2012/066918 patent/WO2013085781A1/en active Application Filing
- 2012-11-29 AP AP2014007675A patent/AP3880A/en active
- 2012-11-29 CN CN201280059917.8A patent/CN103987387B/zh not_active Expired - Fee Related
- 2012-11-29 MX MX2014006824A patent/MX352997B/es active IP Right Grant
- 2012-11-29 AU AU2012348140A patent/AU2012348140B2/en not_active Ceased
- 2012-11-29 SG SG11201402745UA patent/SG11201402745UA/en unknown
- 2012-11-29 US US14/357,825 patent/US9371335B2/en active Active
- 2012-11-29 JP JP2014545947A patent/JP6002778B2/ja not_active Expired - Fee Related
- 2012-11-29 HU HUE12795315A patent/HUE029439T2/en unknown
-
2014
- 2014-05-15 IL IL232654A patent/IL232654A/en active IP Right Grant
- 2014-05-28 ZA ZA2014/03927A patent/ZA201403927B/en unknown
- 2014-10-16 HK HK14110358.9A patent/HK1196943A1/zh not_active IP Right Cessation
-
2016
- 2016-10-17 HR HRP20161351TT patent/HRP20161351T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130969T1 (hr) | Spojevi spiropiperidona kao antagonisti receptora orl-1 | |
HRP20130967T1 (hr) | Spojevi spiropiperidona kao antagonisti receptora orl-1 | |
HRP20161351T1 (hr) | Derivati spirotienopiranopiperidina kao antagonisti receptora orl-1, namijenjeni upotrebi u liječenju ovisnosti o i zloupotrebi alkohola | |
HRP20170363T1 (hr) | Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret) | |
JP2013510870A5 (hr) | ||
SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
HRP20180382T1 (hr) | Inhibitori protein kinaze | |
JP2016516026A5 (hr) | ||
HRP20201746T1 (hr) | Aromatski derivati sulfonamida | |
AR110403A1 (es) | Fungicidas de oxadiazoles | |
HRP20191140T1 (hr) | Spojevi i pripravci kao inhibitori c-kit kinaze | |
JP2019070032A5 (hr) | ||
JP2012518685A5 (hr) | ||
HRP20231089T1 (hr) | Derivati 2,3-dihidro-1h-pirolo[3,4-c]piridin-1-ona kao inhibitori hpk1, namijenjeni liječenju raka | |
RU2016123449A (ru) | Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора | |
HK1209125A1 (en) | Crystalline forms of 1-(5-(5-(3,5-dichloro-4-fluorophenyl)-5- (trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3h-spiro[azetidine-3,1- isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone 1-(5-(5-(35--4-)-5-()-45- -3- )- 3h-[-31-]-1-)-2-() | |
JP2017528519A5 (hr) | ||
RU2009146851A (ru) | Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом | |
JP2013535423A5 (hr) | ||
SI2763982T1 (en) | Substituted benzylindazoles for use as inhibitors of Bub kinase in the treatment of hyperproliferative diseases | |
RU2012133475A (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
MX2015003771A (es) | Formulacion farmaceutica que contiene compuestos de tienotriazolodiazepina. | |
RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы | |
HRP20160539T1 (hr) | Antagonisti trpv4 | |
JP2018524331A5 (hr) |